Article Contents ::
- 1 The Brand Name LOPID Has Generic Salt :: Gemfibrozil
- 2 LOPID Is From Company PFIZER Priced :: Rs. 314.99
- 3 LOPID have Gemfibrozil is comes under Sub class Anti Hyperlipidemics of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hyperlipidemics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name LOPID Has Generic Salt :: Gemfibrozil
LOPID Is From Company PFIZER Priced :: Rs. 314.99
LOPID have Gemfibrozil is comes under Sub class Anti Hyperlipidemics of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hyperlipidemics
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Gemfibrozil | OD TAB | Rs. 314.99 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| LOPID | PFIZER | 900MG | 10 | Rs. 314.99 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From PFIZER :: LOPID | Gemfibrozil | Cardiovascular System | Anti Hyperlipidemics |
Indications for Drugs ::
Hypertriglyceridemia, Hyperlipidemia
Drug Dose ::
Adult: PO 1.2 g/day in 2 divided doses. Maintenance: 0.9-1.5 g/day.
Contraindication ::
Hypersensitivity. Severe hepatic or renal dysfunction; gall stones; neonates, children, pregnancy, lactation.
Drug Precautions ::
Causes of secondary hyperlipidaemia such as hypothyroidism and diabetes must be treated before initiating therapy. Renal impairment; blood disorders. Periodic monitoring of the serum lipids should be done; if no adequate response after 3 mth, treatment should be withdrawn. May increase risk of cholelithiasis.
Drug Side Effects ::
Myositic syndrome, cholelithiasis, GI disturbances, rash, headache, blood dyscrasias, myalgia. Impotence, painful extremities, blurred vision; pruritus, urticaria; impotence; dizziness; cholestatic jaundice. Potentially Fatal: Bone marrow hypoplasia; intracranial haemorrhage; nephrotoxicity; peripheral neuritis.
Pregnancy category ::
3
Drug Mode of Action ::
Gemfibrozil exhibits its action by inhibition of lipolysis and reduction of hepatic fatty acid uptake. It also inhibits secretion of VLDL from the liver.
Drug Interactions ::
Co-admin with repaglinide may increase serum levels of repaglinide. May enhance effects of oral anticoagulants. May also increase the plasma concentrations of ciclosporin and associated nephrotoxicity when used concurrently. Potentially Fatal: Increased risk of myopathy and rhabdomyolysis when used with HMG-CoA reductase inhibitors.
